3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
16
Urogenital Neoplasms
2
Urinary Bladder Neoplasms
2
Urothelial Cancer
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Radiation Injuries
1
Prostate Adenocarcinoma
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Male Urogenital Diseases
1
Lymphatic Metastasis
1
Infiltrating Bladder Urothelial Carcinoma
1
Genital Neoplasms, Male
1
Female Urogenital Diseases
1
Encopresis
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Mitomycin
3
vofatamab
2
pembrolizumab
2
Standard of Care
2
Cystectomy
2
B701 protein, Human herpesvirus 6
2
valrubicin
1
trifluridine tipiracil drug combination
1
testosterone 17 beta-cypionate
1
palbociclib
1
enfortumab vedotin
1
atezolizumab
1
Water
1
Valsartan
1
Urinary Diversion
1
Tranexamic Acid
1
Therapeutics
1
Testosterone Propionate
1
Sunitinib
1
Stents
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Practice Guidelines as Topic
1
Nephrotomy
1
Nephrostomy, Percutaneous
1
Methyltestosterone
1
Immune Checkpoint Inhibitors
1
Ice
1
Hydroxychloroquine
1
Health Information Exchange
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urologic Diseases
×
Radiation Dose Hypofractionation
×
Genitourinary
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled